Blueprint Medicines Corporation Blueprint Medicines Corporation

Blueprint Medicines Corporation

BPMC

Pozycja w akcjach #2355
Blueprint Medicines Corporation is a biopharmaceutical company dedicated to... Blueprint Medicines Corporation is a biopharmaceutical company dedicated to pioneering precision therapies. Its core mission involves developing innovative treatments for various cancers and specific blood disorders, specifically those identified by genomic markers. These efforts extend to patients both within the United States and across international markets. The company's robust pipeline includes several key therapies. AYVAKIT is being advanced for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors. They are also developing BLU-263, a potent, orally administered KIT inhibitor, designed for non-advanced forms of SM and other conditions involving mast cells. Fisogatinib, another orally potent inhibitor, is under development for hepatocellular carcinoma. GAVRETO is being developed to address RET fusion-positive non-small cell lung cancer (NSCLC), various altered solid tumors, and medullary thyroid carcinoma. Furthermore, BLU-701 and BLU-945 are in the pipeline for epidermal growth factor receptor (EGFR)-driven non-small-cell lung carcinoma, while BLU-451 targets NSCLC specifically in patients with EGFR exon 20 insertion mutations. The company's broader pipeline includes BLU-782 for fibrodysplasia ossificans progressiva, BLU-222 for cyclin E aberrant cancers, and BLU-852 for various advanced cancers. To expand its reach and capabilities, Blueprint Medicines has established collaboration and licensing agreements with several partners, including Clementia Pharmaceuticals, Proteovant Therapeutics, CStone Pharmaceuticals, Genentech, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., and Zai Lab (Shanghai) Co., Ltd. Founded in 2008, the company was initially known as Hoyle Pharmaceuticals, Inc., before rebranding to Blueprint Medicines Corporation in June 2011. Its headquarters are located in Cambridge, Massachusetts.
Cena akcji
$129.46
Ostatnia synchronizacja: 2025-07-18
Kapitalizacja rynkowa
$8.36B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Blueprint Medicines Corporation (BPMC)

Kategoria

Healthcare
Historia dywidend dla Blueprint Medicines Corporation (BPMC)
Blueprint Medicines Corporation (symbol giełdowy: BPMC) wypłaciła łącznie 0 dywidend.
Suma wszystkich dywidend (skorygowana o podziały akcji): 0.00
Wskaźnik dywidendy (TTM): 0
Wypłaty dywidend dla Blueprint Medicines Corporation (BPMC) od 2026 do 2026
Roczne wypłaty dywidend
Rok Dywidenda (skorygowana o podziały akcji) Zmień
Za mało danych dla podanych dat.
Lista wszystkich wypłat dywidend
Rok Dywidenda Zmień
Za mało danych dla podanych dat.
Wypłaty dywidend firm podobnych lub konkurencyjnych
Firma Liczba wypłat dywidend Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL